Hospital de Niños "Ricardo Gutiérrez", CABA.
Hospital C. Milstein, CABA.
Am J Hematol. 2016 Oct;91(10):E448-53. doi: 10.1002/ajh.24486. Epub 2016 Aug 22.
Patients with Gaucher type 1 (GD1) throughout Argentina were enrolled in the Argentine bone project to evaluate bone disease and its determinants. We focused on presence and predictors of bone lesions (BL) and their relationship to therapeutic goals (TG) with timing and dose of enzyme replacement therapy (ERT). A total of 124 patients on ERT were enrolled in a multi-center study. All six TG were achieved by 82% of patients: 70.1% for bone pain and 91.1% for bone crisis. However, despite the fact that bone TGs were achieved, residual bone disease was present in 108 patients on ERT (87%) at time 0. 16% of patients showed new irreversible BL (bone infarcts and avascular osteonecrosis) despite ERT, suggesting that they appeared during ERT or were not detected at the moment of diagnosis. We observed 5 prognostic factors that predicted a higher probability of being free of bone disease: optimal ERT compliance; early diagnosis; timely initiation of therapy; ERT initiation dose ≥45 UI/kg/EOW; and the absence of history of splenectomy. Skeletal involvement was classified into 4 major phenotypic groups according to BL: group 1 (12.9%) without BL; group 2 (28.2%) with reversible BL; group 3 (41.9%) with reversible BL and irreversible chronic BL; and group 4 (16.9%) with acute irreversible BL. Our study identifies prognostic factors for achieving best therapeutic outcomes, introduces new risk stratification for patients and suggests the need for a redefinition of bone TG. Am. J. Hematol. 91:E448-E453, 2016. © 2016 Wiley Periodicals, Inc.
阿根廷各地的戈谢病 1 型(GD1)患者参加了阿根廷骨骼项目,以评估骨骼疾病及其决定因素。我们专注于骨骼病变(BL)的存在和预测因素及其与治疗目标(TG)的关系,包括酶替代疗法(ERT)的时间和剂量。共有 124 名接受 ERT 的患者参加了这项多中心研究。所有六个 TG 都被 82%的患者实现:70.1%用于骨痛,91.1%用于骨危机。然而,尽管达到了骨骼 TG,但在开始 ERT 时仍有 108 名患者(87%)存在残留骨骼疾病。尽管接受了 ERT,但仍有 16%的患者出现新的不可逆 BL(骨梗死和缺血性骨坏死),这表明它们出现在 ERT 期间或在诊断时未被发现。我们观察到 5 个预测因素,它们预测骨骼疾病无进展的可能性更高:ERT 依从性最佳;早期诊断;及时开始治疗;ERT 起始剂量≥45 UI/kg/每周;无脾切除术史。根据 BL 将骨骼受累分为 4 个主要表型组:组 1(12.9%)无 BL;组 2(28.2%)有可逆性 BL;组 3(41.9%)有可逆性 BL 和不可逆性慢性 BL;组 4(16.9%)有急性不可逆性 BL。我们的研究确定了实现最佳治疗效果的预测因素,为患者引入了新的风险分层,并表明需要重新定义骨骼 TG。Am. J. Hematol. 91:E448-E453, 2016. © 2016 Wiley Periodicals, Inc.